We are live on
!
Find out more
Puma Biotechnology
PBYI
PBYI
123 hedge funds and large institutions have $362M invested in Puma Biotechnology in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 41 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
36% more call options, than puts
Call options by funds: $4.3M | Put options by funds: $3.17M
2% more capital invested
Capital invested by funds: $356M → $362M (+$6.8M)
7% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 41
2.23% less ownership
Funds ownership: 91.03% → 88.8% (-2.2%)
4% less funds holding
Funds holding: 128 → 123 (-5)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Holders
123
Holders Change
-5
Holders Change %
-3.91%
% of All Funds
2.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
38
Reduced
41
Closed
20
Calls
$4.3M
Puts
$3.17M
Net Calls
+$1.14M
Net Calls Change
+$2.31M
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$11.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.25M |
| 3 |
Morgan Stanley
New York
|
+$3.64M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$2.42M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2M |
Top Sellers
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$12.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.86M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.49M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.26M |
| 5 |
Goldman Sachs
New York
|
-$2.12M |
